Indoramin 20 mg Tablet

Indoramin is indicated in adults for conditions in which alpha blockade is indicated and the management of urinary outflow obstruction due to benign prostatic hyperplasia.

Hyperplasia

Adults:

20 mg twice daily

Dosage may be increased in 20 mg increments at two-weekly intervals up to max. 100 mg per day if required.

Elderly:

20 mg at night may be adequate.

Paediatric population

Not recommended. There is no relevant use of indoramin in the paediatric population

Route of administration

Oral

Patients with established heart failure.

Patients already under treatment with a monoamine oxidase inhibitor.

Special warnings

Incipient cardiac failure should be controlled before treatment with indoramin.

Caution should be observed in prescribing indoramin for patients with hepatic or renal insufficiency.

A few cases of extrapyramidal disorders have been reported in patients treated with indoramin. Caution should be observed in prescribing indoramin in patients with Parkinson's disease.

In animals and in the one reported case of overdose in humans, convulsions have occurred. Due consideration should be given and great caution exercised in the use of indoramin in patients with epilepsy.

The 'Intraoperative Floppy Iris Syndrome' (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during the cataract operation current or part use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery.

Caution should be observed in prescribing indoramin for patients with a history of depression.

Clearance of indoramin may be affected in the elderly. A reduced dose, and/or reduced frequency of dosing may be sufficient in some elderly patients.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose -malabsorption should not take this medicine.

Do not use indoramin in patients being treated with a monoamine oxidase (MAO) inhibitor.

Concomitant use of indoramin with antihypertensive drugs or drugs with hypotensive properties e.g. antidepressants, anxiolytics, hypnotics and moxisylyte, may enhance their hypotensive action. Titration of dosage of the latter may therefore be needed.

Alcohol can increase both the rate and extent of absorption of indoramin, but no untoward effects have been reported at recommended doses.

There are no data from the use of indoramin in pregnant women. Indoramin is not recommended during pregnancy and in women of child bearing potential not using contraception.

It is unknown whether indoramin/ metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from indoramin therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

Drowsiness is sometimes seen in the initial stages of treatment with indoramin or when dosage is increased too rapidly. If drowsiness occurs, patients should be warned not to drive or operate machinery and to avoid CNS depressants including alcohol.

In general, indoramin is well tolerated.

The following undesirable effects have been observed and reported during treatment with indoramin with the following frequencies: Very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Information available at present of the effects of acute overdosage in human beings with indoramin is limited. Effects seen have included deep sedation leading to coma, hypotension and fits.

In cases of overdose QTc prolongation can occur, sometimes complicated by severe arrhythmias, such as Torsades de Pointes.

Results of animal work suggest that hypothermia may also occur.

Suggested therapy is along the following lines:

1. Recent ingestion of large numbers of tablets would require gastric lavage or a dose of ipecacuanha to remove any of the product still in the stomach of the conscious patient.

2. Cardiac monitoring should be initiated immediately and continued for at least 24 hours.

3. Ventilation should be monitored and assisted if necessary.

4. Circulation support and control of hypotension should be maintained.

5. If convulsions occur diazepam may be tried.

Temperature should be closely monitored. If hypothermia occurs, rewarming should be carried out very slowly to avoid possible convulsions.

Pharmacotherapeutic group: Alpha adrenoreceptor antagonist.

Indoramin is an alpha adrenoceptor blocking agent. It acts selectively and competitively on post-synaptic alpha-1 receptors, causing a decrease in peripheral resistance. It also produces relaxation of hyperplastic muscle in the prostate.

Indoramin is rapidly absorbed from Indoramin tablets and has a half-life of about five hours. There is little accumulation during long-term treatment. When three volunteers and four hypertensive patients were treated with radiolabelled indoramin at doses of 40-60 mg daily for up to three days, plasma concentrations reached a peak one to two hours after administration of single doses. Over 90% of plasma indoramin was protein bound. After two or three days 35% of the radioactivity was excreted in the urine and 46% in the faeces. Extensive first pass metabolism was suggested.

Clearance of indoramin may be affected in the elderly. A reduced dose or reduced frequency of dosing may be sufficient in some elderly patients.

Not applicable.

Tablet core

Lactose Monohydrate

Microcrystalline Cellulose

Magnesium Stearate

Polacrillin potassium

Tablet film coat

Opadry yellow 02B520014 which consists of

Hypromellose

Titanium dioxide (E 171)

Polyethylene glycol

Yellow iron oxide (E172)

Black iron oxide (E172)

Not applicable.

36 months.

This medicinal product does not require any special storage conditions.

Tablets are packed in PVC/PVDC – Alu blisters containing 28, 30, 56, 60 & 84 tablets.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.